CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that it has dosed the first patient in a Phase 2b clinical trial in knee osteoarthritis with CRx-102, an oral synergistic combination drug candidate in development for immuno-inflammatory diseases. The trial, COMET-1 (CRx-102 Osteoarthritis Multi-center Evaluation Trial), is designed to evaluate the efficacy of CRx-102 compared to placebo in subjects with symptomatic knee osteoarthritis.
